CYTOFAltamira Therapeutics Ltd.

About Altamira Therapeutics Ltd. (CYTOF)

Altamira Therapeutics Ltd. (CYTOF) is a Biotechnology company headquartered in Hamilton, Bermuda whose shares trade over-the-counter on the OTCQB tier.

Altamira Therapeutics (CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore / SemaPhore platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical de-velopment beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland.

Products and services

Nanoparticles for RNA delivery: development, supply and out-licensing to pharma and biotech companies for use with their poprietary RNA molecules. "Legacy assets": Bentrio nasal spray (drug free and preservative free) for allergic rhinitis; AM-125 (intranasal betahistine) investigational drug for treatment of acute vestibular syndrome (IND open; Phase 2/3)

CYTOF key facts

Ticker symbol

CYTOF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Hamilton, Bermuda

Country of incorporation

BM

Year of incorporation

2014

Employees

14

Estimated market cap

$280.2K (as of Apr 10, 2025)

Shares outstanding

4,662,080

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Altamira Therapeutics Ltd. leadership

• Thomas Meyer — CEO
• Covadonga Paneda — COO
• Marcel Charles Gremaud — CFO
• Mario Barbieri — Chief Accounting Officer
• Joanna de Kalbermatten — Head of IR

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with C